Download Files:

Fasitibant (chloride hydrochloride)

SKU HY-106277A-Get quote Category Tags , ,

Products Details

Product Description

– Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis[1].

Web ID

– HY-106277A

Shipping

– Room temperature

Applications

– Metabolism-protein/nucleotide metabolism

Molecular Formula

– C36H50Cl4N6O6S

References

– [1]S Meini, et al. Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin Eâ‚‚ release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes. Naunyn Schmiedebergs Arch Pharmacol. 2012 Aug;385(8):777-86.|[2]Claudio Valenti, et al. Fasitibant chloride, a kinin Bâ‚‚ receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10.

CAS Number

– 869880-33-1

Molecular Weight

– 836.70

SMILES

– O=C(N(CC1)CCN1C([C@@H](N)CCC[N+](C)(C)C)=O)C2(CCOCC2)N[S](=O)(C(C=CC(Cl)=C3COC4=CC=CC(C(C)=C5)=C4N=C5C)=C3Cl)=O.[Cl-].Cl

Clinical Information

– Phase 2

Research Area

– Metabolic Disease

Solubility

– 10 mM in DMSO

Target

– Bradykinin Receptor

Isoform

– Bradykinin B2 Receptor (B2R)

Pathway

– GPCR/G Protein

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.